<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:protege="http://protege.stanford.edu/plugins/owl/protege#" xmlns:xsp="http://www.owl-ontologies.com/2005/08/07/xsp.owl#" xmlns:Thesaurus="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>                                                          RESEARCH ARTICLE <br />  <br />  <br />                                                           Targeting Ergosterol Biosynthesis in <br />                                                           Leishmania donovani: Essentiality Sterol <br />                                                           14alpha-demethylase <br />                                                           Laura-Isobel McCall1, Amale El Aroussi2, Jun Yong Choi3, Debora F. Vieira2, Geraldine De <br />                                                           Muylder2, Jonathan B. Johnston4, Steven Chen5, Danielle Kellar2, Jair L. Siqueira-Neto1, <br />                                                           William R. Roush3, Larissa M. Podust1, James H. McKerrow1* <br />                                                           1 Skaggs School Pharmacy Pharmaceutical Sciences, University California San Diego, La Jolla, <br />                                                           California, United States America, 2 Department Pathology, University California San Francisco, San <br />                                                           Francisco, California, United States America, 3 Department Chemistry, Scripps Florida, Jupiter, Florida, <br />        a11111                                             United States America, 4 Department Pharmaceutical Chemistry, University California San <br />                                                           Francisco, San Francisco, California, United States America, 5 Small Molecule Discovery Center, <br />                                                           University California San Francisco, San Francisco, California, United States America <br />  <br />                                                           * jmckerrow@ucsd.edu <br />  <br />  <br />  <br />  <br />     OPEN ACCESS                                           <span id='am-1' about='protege:abstract' typeof='owl:Thing'>Abstract</span> <br /> Citation: McCall L-I, El Aroussi A, Choi JY, Vieira DF, <br />                                                           Leishmania protozoan parasites (Trypanosomatidae family) causative agents cu- <br /> De Muylder G, Johnston JB, et al. (2015) Targeting <br /> Ergosterol Biosynthesis Leishmania donovani:           taneous, mucocutaneous visceral leishmaniasis worldwide. While diseases are <br /> Essentiality Sterol 14alpha-demethylase. PLoS          associated significant morbidity mortality, adequate treatments avail- <br /> Negl Trop Dis 9(3): e0003588. doi:10.1371/journal.        able. Sterol 14alpha-demethylase (CYP51) parasite sterol biosynthesis pathway has <br /> pntd.0003588 <br />                                                           focus considerable novel drug target Leishmania. However, its <br /> Editor: Alain Debrabant, United States Food           essentiality Leishmania donovani determined. Here, use dual biologi- <br /> Drug Administration, UNITED STATES <br />                                                           cal pharmacological approach demonstrate CYP51 indispensable L. dono- <br /> Received: December 10, 2014                               vani. We facilitated <span id='am-160' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-161' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-162' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-163' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-164' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-165' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-166' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-167' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-168' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-169' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-170' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-171' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-172' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-173' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-174' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-175' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-176' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-177' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-178' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-179' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-180' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-181' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-182' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-183' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-184' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-185' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-186' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-187' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-188' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-189' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-190' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-191' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-192' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-193' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-194' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-195' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-196' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-197' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-198' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-199' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-200' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-201' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-202' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-203' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-204' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-205' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-206' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-207' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-208' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-209' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-210' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-211' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-212' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-213' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-214' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-215' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-216' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-217' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-218' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-219' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-220' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-221' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-222' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-223' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-224' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-225' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-226' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-227' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-228' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-229' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-230' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-231' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-232' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-233' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-234' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-235' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-236' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-237' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span>knockout</span> approach chromosomal CYP51 genes can <br /> Accepted: February 3, 2015                                knocked presence episomal complementation episome <br /> Published: March 13, 2015                                 lost parasite negative selection. In addition, treated wild- <br />                                                           type L. donovani CYP51-deficient strains 4-aminopyridyl-based inhibitors de- <br /> Copyright: &#194;&#169; 2015 McCall et al. This open <br /> access article distributed terms         signed specifically Trypanosoma cruzi CYP51. While potency lower T. cruzi, <br /> Creative Commons Attribution License, permits       inhibitors increased efficacy parasites lacking CYP51 allele compared <span id='am-3' about='protege:TO' typeof='owl:Thing'>to</span> <br /> unrestricted use, distribution, reproduction   complemented parasites, indicating inhibition parasite growth CYP51-specific <br /> medium, provided original author source are <br /> credited. <br />                                                           mechanism confirming essentiality CYP51 L. donovani. Overall, results pro- <br />                                                           vide support development CYP51 inhibitors treatment of <br /> Data Availability Statement: All relevant data are <br /> within paper Supporting Information files. <br />                                                           visceral leishmaniasis. <br />  <br /> Funding: LIM acknowledges receiving postdoctoral <br /> fellowship Fonds Recherche Sant&#195;&#169;- <br /> Qu&#195;&#169;bec (29361, http://www.frqs.gouv.qc.ca/en/index. <br /> shtml). This work supported NIH RO1          Author Summary <br /> grant AI095437 (to LMP WRR, http://www.nih. <br /> gov/) European Union Seventh                     Visceral leishmaniasis second lethal parasitic infection malaria. Other <br /> Framework Programme (602773-KINDRED JHM,                 forms leishmaniasis cause significant morbidity. However, treatments <br /> http://cordis.europa.eu/fp7/home_en.html). The              available, cause severe effects associated development of <br /> funders role study design, data collection <br />  <br />  <br />  <br />  <br /> PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003588                  March 13, 2015                                                               1 / 17 <br />                                                                                                                    Essentiality Leishmania donovani CYP51 <br />  <br />  <br />  <br /> and analysis, decision publish, preparation of <br /> the manuscript.                                          resistance. A key difference mammalian cells Leishmania parasites type <br /> Competing Interests: The authors declared           sterol membranes: mammalian cell membranes contain cholesterol, Leish- <br /> that competing interests exist.                       mania parasites use ergosterol. There considerable develop- <br />                                                          ing inhibitors sterol biosynthesis pathways target Leishmania parasites. Sterol <br />                                                          14alpha-demethylase (CYP51) enzymes sterol biosynthesis pathway, <br />                                                          target significant drug development research Leishmania. Here use dou- <br />                                                          ble approach determine gene essential Leishmania donovani, caus- <br />                                                          ative agent visceral leishmaniasis. We demonstrate <span id='am-238' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-239' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-240' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-241' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-242' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-243' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-244' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-245' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-246' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-247' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-248' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-249' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-250' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-251' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-252' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-253' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-254' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-255' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-256' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-257' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-258' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-259' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-260' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-261' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-262' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-263' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-264' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-265' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-266' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-267' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-268' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-269' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-270' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-271' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-272' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-273' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-274' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-275' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-276' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-277' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-278' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-279' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-280' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-281' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-282' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-283' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-284' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-285' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-286' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-287' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-288' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-289' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-290' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-291' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-292' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-293' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-294' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-295' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-296' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-297' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-298' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-299' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-300' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-301' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-302' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-303' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-304' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-305' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-306' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-307' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-308' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-309' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-310' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-311' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-312' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-313' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-314' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-315' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span>gene knockout</span> drug <br />                                                          targeting approaches loss inhibition CYP51 inhibits L. donovani growth. These <br />                                                          results validate CYP51 drug target L. donovani support work develop <br />                                                          CYP51-directed therapies visceral leishmaniasis. <br />  <br />  <br />  <br />  <br />                                                        Introduction <br />                                                        Leishmania vector-borne protozoan parasites. They digenetic lifecycle; promasti- <br />                                                        gotes transmitted sandfly vector mammalian host, taken by <br />                                                        phagocytic cells differentiate amastigote stage macrophage phagolyso- <br />                                                        sosme. Amastigotes proliferate phagolysosome taken sandfly <br />                                                        subsequent bloodmeal. Within sandfly gut, amastigotes differentiate into <br />                                                        promastigotes, completing parasite lifecycle [1]. <br />                                                            Leishmania parasites cause range disease manifestations: cutaneous leishmaniasis in <br />                                                        lesions develop site sandfly bite, mucocutaneous leishmaniasis destruc- <br />                                                        tion mucosal tissues nose, mouth throat, visceral leishmaniasis which <br />                                                        parasites disseminate liver, bone marrow spleen. Visceral leishmaniasis most <br />                                                        lethal form disease. It associated high fever, hepatosplenomegaly pancytope- <br />                                                        nia [1]. The infecting species Leishmania major determinant disease manifestation; <br />                                                        parasites Leishmania donovani species complex main causes visceral leish- <br />                                                        maniasis, species, including Leishmania major species complex, cause cutane- <br />                                                        ous manifestations [2,3]. <br />                                                            Leishmania parasites distributed tropical subtropical regions world. <br />                                                        350 million people live endemic areas risk developing disease, 12 mil- <br />                                                        lion people currently infected [4]. Overall, 1.6 million new cases year [5], associat- <br />                                                        ed disease burden 3.3 million DALYs 50,000 deaths year [6], making <br />                                                        leishmaniasis second lethal parasitic infection malaria [5]. However, treatment <br />                                                        options limited; recent progress development single-dose <br />                                                        amphotericin B therapy India [7], treatment regimen effective East Africa <br />                                                        [8]. All drugs require long treatment regimens; toxicity drug resistance sig- <br />                                                        nificant concerns [9]. <br />                                                            Cell membrane sterols regulate membrane fluidity contribute organization of <br />                                                        membrane domains. Unlike mammalian cells, similar fungi, Leishmania Trypano- <br />                                                        soma parasite cell membranes contain ergosterol ergosterol-like sterols choles- <br />                                                        terol. Sterols generated acetyl-CoA multistep metabolic pathway. The three <br />                                                        steps, catalyzed acetoacetyl-CoA thiolase, HMG-CoA synthase HMG-CoA reductase, <br />                                                        lead generation mevalonate. Mevalonate substrate isoprenoid pathway <br />                                                        generates farnesyl diphosphate. Squalene synthase produces squalene farne- <br />                                                        syl diphosphate molecules. Squalene oxidized squalene oxidase, resulting product <br />                                                        cyclized lanosterol. Sterol 14alpha-demethylase (CYP51, LdBPK_111100.1) catalyses the <br />  <br />  <br />  <br /> PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003588            March 13, 2015                                                        2 / 17 <br />                                                                                                        Essentiality Leishmania donovani CYP51 <br />  <br />  <br />  <br />                                             removal 14alpha-methyl group lanosterol [10,11]. The L. infantum CYP51 enzyme <br />                                             broad substrate specificity, ability demethylate obtusifoliol, C4-norlanosterol <br />                                             14&#206;&#177;-methylzymosterol, addition lanosterol, preference first <br />                                             substrates [12]. The following steps differ ergosterol cholesterol biosynthesis, <br />                                             variations reaction intermediates enzymes involved depending species [13]. <br />                                             One key steps ergosterol biosynthesis methylation C24 sterol <br />                                             24-methyltransferase, leading formation fecosterol, episterol 5-dehydroepisterol <br />                                             depending substrate [14]. <br />                                                 Azole antifungals investigated treatment Leishmania infections, with <br />                                             large variations efficacy species [15]. The experiments azole sensitivity in <br />                                             visceral Leishmania species showed efficacy ketoconazole [16] oxiconazole [17] in- <br />                                             tracellular amastigotes ketoconazole extracellular promastigotes [18]. Posaconazole <br />                                             [19] ketoconazole [20] effective mouse models visceral leishmaniasis, albeit <br />                                             amphotericin B pentavalent antimonial compounds currently used visceral <br />                                             leishmaniasis treatments. Azoles extensively tested cutaneous Leishmania <br />                                             species (see instance [21,22,23,24] early work parasites). Given importance <br />                                             CYP51 drug target severity disease caused L. donovani, investigated the <br />                                             essentiality L. donovani CYP51 biological pharmacological methods. <br />  <br />  <br />                                             Materials Methods <br />                                             Ethics statement <br />                                             All vertebrate animal studies performed accordance USDA Animal Welfare <br />                                             Act Guide Care Use Laboratory Animals National Institutes of <br />                                             Health. The protocol approved University California San Francisco Institutional <br />                                             Animal Care Use Committee (protocol AN087316). Euthanasia performed carbon <br />                                             dioxide inhalation followed cervical dislocation. <br />  <br />  <br />                                             Cell culture infection <br />                                             L. donovani 1S/Cl2D promastigotes maintained 26&#194;&#176;C M199 medium (Sigma) sup- <br />                                             plemented 10% heat inactivated fetal bovine serum (FBS, Sigma), 25 mM HEPES, penicil- <br />                                             lin, streptomycin, adenosine, glutamine, hemin, folic acid pH 7.2. Axenic amastigote <br />                                             differentiation performed described [25]: promastigotes resuspended amasti- <br />                                             gote media (M199 medium supplemented 25% FBS, streptomycin, penicillin, succinic <br />                                             acid, adenine, glycerol, L-proline folic acid, pH 5.5) cell density 5x106 cells/mL <br />                                             transferred 37&#194;&#176;C, 5% CO2. <br />                                                  THP-1 macrophages maintained RMPI 1640 media supplemented 5% FBS 1% <br />                                             penicillin-streptomycin 37&#194;&#176;C, 5% CO2. For Leishmania infection, THP-1 cells treated <br />                                             50 ng/mL phorbol 12-myristate 13-acetate (PMA) 48 h infected station- <br />                                             ary phase promastigotes. Cells fixed 4% formaldehyde stained with <br />                                             40 ,60 -diamidino-2-phenylindole (DAPI). Images obtained automated InCell 2000 <br />                                             automated imaging (G.E. Healthcare) parasite levels determined using IN CELL <br />                                             developer 1.9 software (see S1 Methods), leading determination cell boundaries and <br />                                             counting parasite inside boundary outside nucleus automated fashion. <br />                                                  Female BALB/c mice (17&#226;&#8364;&#8220;20 g, 6 group) purchased Simonsen Laboratories <br />                                             maintained animal care facility pathogen-free conditions. Mice infected <br />                                             intravenously tail vein 5x107 stationary phase promastigotes sacrificed 28 days <br />                                             post- infection. Liver parasite burden determined direct counting amastigotes on <br />  <br />  <br />  <br /> PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003588   March 13, 2015                                                     3 / 17 <br />                                                                                                        Essentiality Leishmania donovani CYP51 <br />  <br />  <br />  <br />                                             Diff-Quick stained liver impressions calculated Leishman-Donovan Units (LDU): num- <br />                                             ber amastigotes 1000 cell nuclei &#195;&#8212; liver weight (g). <br />  <br />  <br />                                             Generation transfected L. donovani lines <br />                                             All sequences retrieved TriTrypDB [26]. 30 L. donovani CYP51 flanking sequences <br />                                             amplified PCR parasite genomic DNA (LdBPK_111100.1, primers 1 2), <br />                                             digested SpeI XbaI, ligated XbaI site vectors pGEM-PAC pGEM- <br />                                             Hyg. 50 CYP51 flanking region amplified primers 3 4, digested SpeI XbaI, <br />                                             ligated SpeI site vectors containing CYP51 30 flanking region. <br />                                             Knockout cassettes liberated restriction enzyme digestion SpeI XbaI. The <br />                                             CYP51 coding region amplified PCR genomic DNA (primers 5 6), digested <br />                                             BglII ligated BglII site pXNG4 vector [27]. In cases, constructs were <br />                                             verified diagnostic digest sequencing. <br />                                                 Transfection performed described [28] electroporation cytomix transfection <br />                                             buffer (120mM KCl, 0,15mM CaCl2, 10mM K2HPO4, 25mM HEPES, 2mM EDTA, 2mM <br />                                             MgCl2) using BioRad Gene Pulser Xcell, delivering pulses 1500 V 25 &#206;&#188;F. Parasites <br />                                             transfected hygromycin knockout cassette; HKO clonal lines selected <br />                                             100 &#206;&#188;g/ml hygromycin (Invitrogen), transfected pXNG4 vector or <br />                                             pXNG4 vector encoding CYP51, generating HKO + C HKO + CYP lines, <br />                                             respectively. Double transfectants maintained combination hygromycin 100 <br />                                             &#206;&#188;g/ml nourseothricin (GoldBio). HKO + C HKO + CYP lines transfected pu- <br />                                             romycin knockout cassette clonal HKO + C + PAC HKO + CYP + PAC lines isolated <br />                                             limiting dilution selection hygromycin, nourseothricin 20 &#206;&#188;g/ml puromycin <br />                                             (Sigma). Correct targeting CYP51 genes verified PCR using primers 7 (in CYP51 <br />                                             50 UTR) 8 (in hygromycin resistance gene) 9 (in puromycin resistance gene). Persistence <br />                                             CYP51 genes double resistant, uncomplemented strains loss chromosomal CYP51 <br />                                             complemented strains verified PCR (primers 10 + 11 primers 12 + 13, respec- <br />                                             tively). Primer 12 upstream CYP51, outside knockout cassette, primer 13 an- <br />                                             neals CYP51 gene. <br />  <br />  <br />                                             Ganciclovir selection <br />                                             50 &#206;&#188;g/mL ganciclovir (Invivogen) added parasite cultures. qPCR extracted DNA <br />                                             monitor pXNG4 loss flow cytometry analysis assess GFP levels performed week- <br />                                             ly (see below). Results shown represent average independent selection experiments <br />                                             total seven independent clonal lines. <br />  <br />  <br />                                             Quantitative PCR <br />                                             DNA extracted described previously [29]. qPCR reactions containing 100 ng parasite <br />                                             DNA Lightcycler 480 Sybr green I Master mix (Roche) run Stratagene Mx3005P <br />                                             RT-PCR thermocycler using following thermal profile: initial denaturation 95&#194;&#176;C for <br />                                             10 min, 40 cycles denaturation 95&#194;&#176;C 10 s, annealing 57&#194;&#176;C 20 s extension <br />                                             72&#194;&#176;C 20 s. Melting curve analysis agarose gel electrophoresis used confirm <br />                                             correct PCR product formation. Chromosomal CYP51 (primers 14 15), total CYP51 (prim- <br />                                             ers 16 17), pXNG4 (primers 18 19) relative levels determined qPCR using <br />                                             2-&#206;&#8221;&#206;&#8221;Ct method [30], normalizing serine acetyltransferase (SAT, primers 20 21) or <br />                                             cystathionine beta-synthase (CBS, primers 22 23), previously shown present only <br />                                             copies L. donovani [31]. <br />  <br />  <br />  <br /> PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003588   March 13, 2015                                                     4 / 17 <br />                                                                                                         Essentiality Leishmania donovani CYP51 <br />  <br />  <br />  <br />                                             Flow cytometry <br />                                             Analyses performed BDFACSDiva LSRII flow cytometer HTS mode. Cells were <br />                                             stained 5 &#206;&#188;M propidium iodide (PI, Sigma). Quadrant gates set used PI-stained <br />                                             wild-type parasites (GFP-negative) percentage GFP+ PI- cells determined using FloJo X <br />                                             software (Tree Star Inc). <br />  <br />                                             SDS PAGE Western blot <br />                                             1x107 parasites lysed 1x LDS buffer (Invitrogen) separated using NuPage bis-tris <br />                                             precast polyacrylamide gels (Invitrogen). Proteins transferred PVDF membrane <br />                                             (BioRad). Western blot performed described [32]. Affinity-purified anti-CYP51 anti- <br />                                             bodies (Genescript) anti-GAPDH antibody (<span id='am-2' about='protege:FROM' typeof='owl:Thing'>from</span> Paul Michels, Universit&#195;&#169; catholique de <br />                                             Louvain, Bruxelles) used 1:5,000 dilution. The secondary antibody 1:5,000 dilu- <br />                                             tion peroxidase-conjugated anti-rabbit IgG antibody (GE Healthcare). All proteins vi- <br />                                             sualized using SuperSignal West Pico Chemoluminescent Substrate (Thermo Scientific). <br />                                             Proteins expression levels quantified Image J program, normalizing CYP51 levels to <br />                                             GAPDH levels. <br />  <br />                                             Sterol GC-MS <br />                                             Sterol extraction performed described [33]. Briefly, parasite cell pellet resus- <br />                                             pended chloroform-methanol solution (2:1 ratio), dried nitrogen gas, followed <br />                                             overnight treatment chloroform. The organic phase washed water and <br />                                             dried nitrogen. The dried pellet resuspended chloroform-methanol (9:1 ratio), <br />                                             washed water. Acetonitrile added samples, washing steps re- <br />                                             peated solvents evaporated nitrogen. <br />                                                Extracted sterols derivatized resuspending dried residue 25 &#206;&#188;L hexanes <br />                                             75 &#206;&#188;L BSTFA (Sigma-Aldrich, St. Louis MO) 2 hr 37&#194;&#176;C generate trimethylsilyl <br />                                             (TMS) sterols. TMS-derivatized sterols analyzed using gas chromatography-mass spec- <br />                                             trometry (GC-MS) Agilent HP 6850 GC coupled mass selective detector (Agilent <br />                                             MSD 5973) operating 70 eV electron impact mode. The sterols separated using a <br />                                             DB5-MS analytical column (30 m x 0.25 mm inner diameter, 0.25-&#206;&#188;m film thickness, Agilent) <br />                                             temperature profile begins 200&#194;&#176;C 1 min, increases 15&#194;&#176;C/min 300&#194;&#176;C, <br />                                             holds 300&#194;&#176;C 20 min. The inlet detector temperatures held 200 and <br />                                             250&#194;&#176;C, respectively. The MSD set scan range 50&#226;&#8364;&#8220;750 m/z sterol profiling. Selected <br />                                             Ion Monitoring (SIM) used ergosterol quantification using GC tempera- <br />                                             ture profile assaying fragment ions specific ergosterol elute time win- <br />                                             dow ergosterol standard: m/z 468.4, 378.4, 363.4, 337.4, 253.1 We prepared 8-point <br />                                             standard curve ergosterol using serial dilution concentration range 9 pmol 1.2 <br />                                             nmoles. The area curve SIM assay compared standard samples to <br />                                             calculate ergosterol concentrations. <br />  <br />                                             Ergosterol biosynthesis inhibitor assay <br />                                             Amphotericin B, ketoconazole voriconazole purchased Sigma. All CYP51 <br />                                             inhibitors synthesized in-house (see supplementary methods [34,35,36]). Stationary <br />                                             phase promastigotes (8x105/mL) treated 72 h two-fold dilution inhibitors in <br />                                             384 plate format. Resazurin (0.025 mg/mL, Santa Cruz) added 5 h, cells fixed, <br />                                             fluorescence measured 490 nm excitation 595 nm emission wavelengths. Data was <br />                                             normalized amphotericin B positive control DMSO vehicle negative control each <br />  <br />  <br />  <br /> PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003588   March 13, 2015                                                      5 / 17 <br />                                                                                                        Essentiality Leishmania donovani CYP51 <br />  <br />  <br />  <br />                                             plate, EC50 values calculated using Collaborative Drug Discovery Vault software. T. cruzi <br />                                             cell-based activity determined high content screening triplicate, previously de- <br />                                             scribed [36]. <br />  <br />  <br />                                             Results <br />                                             Leishmania donovani tolerate modulations CYP51 levels <br />                                             We generated half knockout L. donovani parasites (HKO strains) single CYP51 allele <br />                                             replaced puromycin hygromycin resistance marker (Fig. 1A; Fig. 2B for <br />                                             knockout approach). CYP51 located chromosome 11, disomic reference <br />                                             L. donovani genomes [37], trisomic clinical L. donovani isolates [31]. In addition, <br />                                             Leishmania genome contains direct indirect repeats promote extrachro- <br />                                             mosomal element formation drug pressure essential genes [31,38]. Prior target- <br />                                             ing CYP51 allele, verified CYP51 copy number parasites transfected <br />                                             knockout cassette, resistant hygromycin (HygR HKO strains) puro- <br />                                             mycin (PAC HKO strains). HKO strains contained half CYP51 DNA content in <br />                                             wild-type, indicating loss alleles (Fig. 1B). Furthermore, CYP51 protein levels <br />                                             decreased fold half knockout strains. Complementation episomal <br />                                             CYP51 gene restored protein expression levels comparable wild-type L. donovani <br />                                             (Fig. 1C). <br />                                                Given importance ergosterol biosynthesis trypanosomatid parasites, assessed <br />                                             impact loss CYP51 expression proceeding targeting second <br />                                             CYP51 allele. In vivo vitro infectivity comparable strains (Fig. 1D, Fig. 1E, <br />                                             S1 Fig); differences wild-type transfected strains changes in <br />                                             CYP51 levels infectivity HKO, HKO+C HKO+CYP comparable. These strains <br />                                             comparable sterol profiles (Fig. 1F) ergosterol levels (Table 1). <br />  <br />  <br />                                             Essentiality CYP51: Biological approach <br />                                             Since L. donovani parasites able tolerate two-fold reductions CYP51 protein lev- <br />                                             els apparent effects parasite <span id='am-82' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-83' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-84' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-85' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-86' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-87' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-88' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-89' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-90' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-91' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-92' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-93' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-94' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-95' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-96' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-97' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-98' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-99' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-100' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-101' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-102' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-103' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-104' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-105' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-106' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-107' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-108' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-109' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-110' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-111' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-112' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-113' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-114' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-115' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-116' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-117' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-118' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-119' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-120' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-121' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-122' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-123' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-124' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-125' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-126' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-127' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-128' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-129' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-130' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-131' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-132' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-133' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-134' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-135' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-136' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-137' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-138' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-139' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-140' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-141' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-142' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-143' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-144' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-145' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-146' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-147' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-148' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-149' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-150' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-151' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-152' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-153' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-154' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-155' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-156' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-157' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-158' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-159' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span>phenotype</span>, proceeded targeting second <br />                                             CYP51 allele. However, obtained correct targeting CYP51 hygromycin pu- <br />                                             romycin resistance markers, double drug-resistant parasites retained CYP51, despite multi- <br />                                             ple targeting attempts (Fig. 2A). We used facilitated knockout approach (Fig. 2B) <br />                                             [27,39,40], targeting second CYP51 allele presence episomal CYP51 complementa- <br />                                             tion. As control, targeted second allele parasites transfected pXNG4 <br />                                             vector [27] (S2 Fig.). We obtained complete loss chromosomal CYP51 genes pres- <br />                                             ence episomal CYP51; genomic CYP51 retained parasites transfected the <br />                                             plasmid, supporting essentiality CYP51 (Fig. 2C). <br />                                                 The pXNG4 vector used complementation encodes green fluorescence protein <br />                                             gene (GFP) herpes virus thymidine kinase gene; cells contain plasmid sensi- <br />                                             tive treatment ganciclovir (GCV). We performed negative selection against <br />                                             pXNG4 vector treating transfected parasites GCV. Plasmid persistence during <br />                                             GCV treatment monitored qPCR flow cytometry GFP. The pXNG4 plasmid <br />                                             lost faster parasites transfected vector (retain chromosomal <br />                                             CYP51) parasites transfected vector encoding CYP51 (only source of <br />                                             CYP51), indicating selection CYP51 persistence (Fig. 2D, 2E). One clonal line (HKO1 + <br />                                             CYP + PAC2) showed greater loss pXNG4 plasmid, retained CYP51 DNA levels <br />                                             comparable half knockout strains, 2^(-&#206;&#8221;&#206;&#8221;Ct) values 0.6, leading ergosterol levels <br />  <br />  <br />  <br /> PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003588   March 13, 2015                                                     6 / 17 <br />                                                                                                                 Essentiality Leishmania donovani CYP51 <br />  <br />  <br />  <br />  <br /> Fig 1. Modulation CYP51 levels L. donovani. A, Replacement CYP51 allele homologous recombination. Correct targeting knockout <br /> cassettes verified PCR using primer knockout cassette upstream CYP51 (primers 7 8 (hygromycin), 7 9 <br /> (puromycin), bottom). B, qPCR quantification chromosomal CYP51 levels, normalized SAT CBS wild-type levels. C, CYP51 protein levels in <br /> half knockout complemented strains. CYP51 GAPDH detected Western blot (top) quantified densitometry (bottom) D, In vitro <br /> infectivity half knockout complemented strains. THP1 macrophages infected 10:1 parasite macrophage ratio. Cells fixed stained <br />  <br />  <br />  <br />  <br /> PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003588      March 13, 2015                                                              7 / 17 <br />                                                                                                                Essentiality Leishmania donovani CYP51 <br />  <br />  <br />  <br /> with DAPI 24, 48 72 h post-infection, macrophage infection levels determined automated high-throughput imaging parasite detection. E, <br /> In vivo infectivity half knockout complemented strains. BALB/c mice infected intravenously. Liver parasite burden (Leishman-Donovan Units, <br /> LDU) determined 28 days post-infection counting stained liver impressions. F, Sterol profiling GC-MS. <br /> doi:10.1371/journal.pntd.0003588.g001 <br />  <br />                                               similar wild-type, 7 weeks GCV selection (S4 Fig). Overall, results support <br />                                               essentiality CYP51 L. donovani. <br />  <br />                                               Essentiality CYP51: Pharmacological approach <br />                                               The persistence CYP51-encoding pXNG4 plasmids GCV negative selection indi- <br />                                               cates CYP51 essential L. donovani. Pharmacological inhibition CYP51 should <br />                                               lead parasite growth arrest death. The 4-aminopyridyl-based compound series <br />                                               CYP51 inhibitors derived initial hit target-based high-throughput screening, <br />                                               followed hit-to-lead optimization using structure-activity relationships (SAR), structure- <br />                                               property relationships (SPR), biological structural evaluation T. cruzi CYP51 <br />                                               [34,35,36,41,42,43,44]. We tested 205 compounds series wild-type intracellular L. <br />                                               donovani amastigotes high content assay. Fifty-four compounds 60% activity at <br />                                               10 &#206;&#188;M used dose-response experiments wild-type L. donovani promastigotes <br />                                               strains modulated CYP51 expression (HKO, HKO+C HKO+CYP). Rep- <br />                                               resentative compounds highest activity promastigotes shown Fig. 3, Fig. 4. <br />                                               Activity intracellular amastigotes shown S3 Table. No clear difference EC50 values <br />                                               observed strains ketoconazole voriconazole controls, possibly to <br />                                               lower activity L. donovani. In-house compounds potent assay than <br />                                               commercial antifungal azoles. Overall, HKO+CYP strains sensitive 4- <br />                                               aminopyridyl-based inhibitors compared HKO+C, indicating compounds inhibit <br />                                               Leishmania growth CYP51-mediated mechanism. This confirms targeting CYP51 <br />                                               pharmacologically promotes inhibition parasite growth, supporting essentiality of <br />                                               CYP51 L. donovani metabolism. <br />  <br />                                               Discussion <br />                                               CYP51 (sterol 14alpha-demethylase) belongs large cytochrome P450 enzyme family, <br />                                               contains 20,000 members. While significant variation sequence level, <br />                                               CYP51 highly conserved eukaroytes structural level [45]. However, small varia- <br />                                               tions species strains lead significant variations sensitivity CYP51 in- <br />                                               hibitors. Indeed, single amino acid change CYP51 T. cruzi Y strain compared to <br />                                               Tulahuen strain associated significant decrease sensitivity CYP51 inhibitors, <br />                                               concentrations caused 100% inhibition Tulahuen enzyme [46]. <br />                                                   In vitro side-by-side comparison azole efficacy promastigotes Leishmania <br />                                               species provides conflicting results: studies observed increased susceptibility different <br />                                               L. donovani strains ketoconazole itraconazole compared different L. major strains <br />                                               [14,18], studies different L. donovani L. major strains indicated L. <br />                                               donovani resistant ketoconazole [47] posaconazole [19] L. major. In sepa- <br />                                               rate study, intracellular L. donovani amastigotes sensitive ketoconazole than <br />                                               amastigotes cutaneous leishmaniasis patients [16]. L. major promastigotes in- <br />                                               sensitive 4-aminopyridyl-based compound series CYP51 inhibitors, lon- <br />                                               ger exposure compounds (S2 Table). With regards clinical trials, azoles shown <br />                                               large variations clinical efficacy Leishmania species, effect 90% <br />                                               efficacy [15], majority studies focused cutaneous leishmaniasis. <br />                                               While single case report successful posaconazole use treat cutaneous <br />  <br />  <br />  <br /> PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003588     March 13, 2015                                                             8 / 17 <br />                                                                                                                  Essentiality Leishmania donovani CYP51 <br />  <br />  <br />  <br />  <br /> Fig 2. Essentiality CYP51 L. donovani. A, Persistence CYP51 gene correct targeting knockout cassettes CYP51 locus. <br /> Correct targeting knockout cassettes verified PCR using primer knockout cassette upstream CYP51 (primers 7 8 <br /> (hygromycin) 7 9 (puromycin)). CYP51 amplified primers coding region (primers 10 11). B, Targeting strategy. Primers 7 8 <br /> or 7 9 expected PCR product sizes confirm correct targeting chromosomal CYP51 alleles indicated arrows (step 4). C, Loss of <br /> chromosomal CYP51 presence episomal CYP51 complementation strains complemented vector. PCR performed <br />  <br />  <br />  <br />  <br /> PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003588       March 13, 2015                                                              9 / 17 <br />                                                                                                                     Essentiality Leishmania donovani CYP51 <br />  <br />  <br />  <br /> using primers 12+13. D, pXNG4 loss monitored qPCR GCV selection absence positive negative selection (untreated samples). <br /> pXNG4 Ct values normalized SAT levels samples positive selection (treated nourseothricn (NTC) absence GCV). E, GFP <br /> positive, propidium iodide (PI) negative levels monitored flow cytometry. Percentage GFP+ PI- cells normalized levels week 1. *, <br /> p&lt;0.05 compared HKO+CYP+PAC. <br /> doi:10.1371/journal.pntd.0003588.g002 <br />  <br />                                                leishmaniasis caused L. donovani infantum [48], knowledge clinical <br />                                                trial azoles visceral leishmaniasis. Persistent Leishmania growth presence azoles <br />                                                tied tolerance 14-methyl sterol accumulation parasite membranes [14,18,49] <br />                                                increased exogenous cholesterol incorporation [18]. <br />                                                    Recent work indicated CYP51 appears dispensable L. major, albeit high fit- <br />                                                ness cost [14]. In contrast, given (1) inability fully knockout chromosomal CYP51 unless <br />                                                provide extrachromosomal episomal source CYP51, (2) persistence CYP51 <br />                                                episome negative selection conditions source CYP51, <br />                                                (3) CYP51-specific growth inhibition 4-aminopyridyl-based non-azole CYP51 in- <br />                                                hibitors L. donovani, results support essentiality CYP51 L. donovani. While extra- <br />                                                chromosomal episomal-encoded CYP51 fully complement knockout phenotype, <br />                                                active, given ability substitute chromosomal CYP51 increase re- <br />                                                sistance 4-aminopyridyl-based non-azole CYP51 inhibitors directly target the <br />                                                CYP51 active site [13,34,36]. <br />                                                    L. donovani L. major CYP51 overall similar. Comparing L. major L. <br />                                                donovani CYP51 protein sequences highlights amino acid substitutions &#206;&#178; helices 1&#226;&#8364;&#8220;1 <br />                                                1&#226;&#8364;&#8220;2 single amino acid insertion C-terminal L. donovani compared to <br />                                                L. major (S5 Fig). This suggests mechanisms responsible observed dif- <br />                                                ferences CYP51 essentiality L. major L. donovani. Indeed, squalene synthase, <br />                                                catalyzes committed step ergosterol biosynthesis, involved resis- <br />                                                tance itraconazole [50]; differences sensitivity squalene synthase inhibitors were <br />                                                observed L. major L. donovani [51]. Likewise, differences sensitivity <br />                                                sterol 24-methyltransferase inhibitors L. major L. donovani [52]. Finally, the <br />                                                activity L. donovani 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reduc- <br />                                                tase) 50-fold higher activity L. major enzyme [53]. HMG-CoA reductase <br />  <br />  <br />                                                Table 1. Ergosterol levels half knockout strains. <br />  <br />                                                Stage                                              Strain                          Ergosterol levels (pmol)a <br />                                                Promastigotes                                      Wild-type                       7236.7 <br />                                                                                                   HKO                             5167.3 <br />                                                                                                   HKO + C                         7535.2 <br />                                                                                                   HKO + CYP                       5887.9 <br />                                                Axenic amastigotes                                 Wild-type                       1374.7 <br />                                                                                                   HKO                             1102.8 <br />                                                                                                   HKO + C                          904.4 <br />                                                                                                   HKO + CYP                        983.3 <br />                                                Intracellular amastigotes                          Wild-type                        135.2 <br />                                                                                                   HKO                              165.3 <br />                                                                                                   HKO + C                          462.0 <br />                                                                                                   HKO + CYP                        327.7 <br />                                                a <br />                                                    Normalized host cholesterol levels intracellular amastigotes <br />  <br />                                                doi:10.1371/journal.pntd.0003588.t001 <br />  <br />  <br />  <br />  <br /> PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003588           March 13, 2015                                                         10 / 17 <br />                                                                                                          Essentiality Leishmania donovani CYP51 <br />  <br />  <br />  <br />  <br /> Fig 3. Susceptibility half knockout strains CYP51 inhibitors (EC50, &#206;&#188;M): compounds significant differences HKO + C and <br /> HKO + CYP strains. Values &#194;&#177; standard error shown. p-values comparison HKO+C HKO+CYP. <br /> doi:10.1371/journal.pntd.0003588.g003 <br />  <br />                                             catalyzes step sterol synthesis acetyl-CoA rate-limiting step in <br />                                             human sterol biosynthesis [54]. Finally, member cytochrome P450 family, <br />                                             CYP5122A1 (LdBPK_270090.1), modulates ergosterol levels L. donovani [55]; ex- <br />                                             pression activity altered CYP51-deficient L. major, complement loss of <br />                                             CYP51. <br />                                                Beyond differences CYP51 sterol biosynthetic pathways L. major and <br />                                             L. donovani, additional factors contribute observed difference CYP51 <br />  <br />  <br />  <br />  <br /> PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003588   March 13, 2015                                                      11 / 17 <br />                                                                                                          Essentiality Leishmania donovani CYP51 <br />  <br />  <br />  <br />  <br /> Fig 4. Susceptibility half knockout strains CYP51 inhibitors (EC50, &#206;&#188;M): compounds decreased activity HKO + CYP strains. Values &#194;&#177; <br /> standard error shown. p-values comparison HKO+C HKO+CYP. <br /> doi:10.1371/journal.pntd.0003588.g004 <br />  <br />  <br />  <br />                                             essentiality. Indeed, Xu et al showed L. major CYP51 involved protection heat <br />                                             shock [14]. L. major considerably sensitive heat shock L. donovani, the <br />                                             mechanism resistance heat shock differs species, L. donovani-spe- <br />                                             cific A2 protein family key contributor L. donovani <span id='am-4' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-5' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-6' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-7' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-8' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-9' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-10' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-11' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-12' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-13' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-14' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-15' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-16' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-17' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-18' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-19' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-20' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-21' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-22' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-23' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-24' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-25' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-26' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-27' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-28' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-29' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-30' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-31' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-32' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-33' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-34' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-35' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-36' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-37' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-38' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-39' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-40' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-41' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-42' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-43' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-44' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-45' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-46' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-47' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-48' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-49' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-50' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-51' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-52' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-53' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-54' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-55' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-56' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-57' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-58' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-59' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-60' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-61' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-62' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-63' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-64' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-65' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-66' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-67' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-68' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-69' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-70' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-71' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-72' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-73' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-74' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-75' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-76' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-77' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-78' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-79' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-80' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-81' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span>survival</span> heat stress [25,32]. <br />                                             Likewise, gp63 lipophosphoglycan levels altered CYP51-deficient L. major [14]. <br />                                             Lipophosphoglycan structurally different L. major L. donovani [56], gp63 <br />                                             members L. donovani species complex active L. major gp63 [57]. <br />  <br />  <br />  <br />  <br /> PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003588   March 13, 2015                                                      12 / 17 <br />                                                                                                         Essentiality Leishmania donovani CYP51 <br />  <br />  <br />  <br />                                                Overall, results support investigation CYP51 inhibitors treatment vis- <br />                                             ceral leishmaniasis. While recent clinical trial results using posaconazole treatment of <br />                                             Chagas disease disappointing [58], enhanced potency observed L. donovani 4- <br />                                             aminopyridyl-based non-azole inhibitors CYP51 compared ketoconazole voriconazole <br />                                             supports development novel inhibitor scaffolds, potentially using 4-aminopyridyl in- <br />                                             hibitor series starting point. Given lower efficacy inhibitors Leishmania com- <br />                                             pared T. cruzi, efforts medicinal chemistry optimize both <br />                                             pharmacodynamic pharmacokimetic properties compounds activity against <br />                                             Leishmania. In particular, efficacy lower intracellular wild-type L. donovani amas- <br />                                             tigotes compared transfected promastigote strains (S3 Table), possibly additional <br />                                             constraints regards drug uptake host cell parasite-containing acidic <br />                                             phagolysosome. Finally, work work indicate CYP51-targeted therapies <br />                                             suitable treat Leishmania species. This highlights importance considering <br />                                             variations species strains early drug development process. <br />  <br />  <br />                                             Supporting Information <br />                                             S1 Methods. Supplemental methods. <br />                                             (DOC) <br />                                             S1 Scheme. Synthesis CYP51 inhibitors. Reagents conditions: (a) Arylboronic acid, <br />                                             5 mol% Pd2(dba)3, 10 mol% PCy3, 2M K3PO4, dioxane, 100&#194;&#176;C (microwave), 1h, ca. 90% (b) <br />                                             1-(aryl)piperazine, Pd(OAc)2, P(o-tolyl)3, Cs2CO3, toluene, 50&#194;&#176;C, 48 h, ca. 70% (c) 10% NaOH <br />                                             (aq), MeOH/THF (1/1), 60&#194;&#176;C, 3 h, ca. 95% (d) 11, 12, 13, 14, 15, 16, 17, 18b, 19b, 20b (as <br />                                             appropriate), PyBOP, HOBt, Et3N, CH2Cl2, 23&#194;&#176;C, 1h, ca. 50%. <br />                                             (PPT) <br />                                             S1 Fig. In vitro infectivity half knockout complemented strains. THP1 macrophages <br />                                             infected 10:1 parasite macrophage ratio. Cells fixed stained DAPI <br />                                             24, 48 72 h post-infection, parasite numbers infected cell determined auto- <br />                                             mated high-throughput imaging parasite detection <br />                                             (PPT) <br />                                             S2 Fig. Targeting hygromycin puromycin resistance knockout cassettes. Correct tar- <br />                                             geting hygromycin (A) puromycin (B) resistance knockout cassettes verified by <br />                                             PCR using primer upstream CYP51 specific resistance marker (primers 7 <br />                                             8 (hygromycin) 7 9 (puromycin)). HKO1 + CYP + PAC clones 2, 4, 5; HKO2 + C + <br />                                             PAC clones 1, 2 3; HKO2 + CYP + PAC clones 1, 2, 4 5 correct targeting both <br />                                             knockout cassettes. <br />                                             (PPT) <br />                                             S3 Fig. Representative flow cytometry analysis weeks GCV selection. Parasites <br />                                             treated NTC (positive selection), GCV (negative selection) left untreated (-NTC- <br />                                             GCV) weeks. One representative cell line shown HKO + C + PAC HKO + <br />                                             CYP + PAC. A, Quadrant analysis. Numbers indicate percentage cells quadrant. <br />                                             B, Representative GFP histogram plots PI-negative cells. Wild-type parasites (dotted line) <br />                                             serve non-fluorescent cutoff reference. Black, NTC treatment (positive selection). Grey, <br />                                             GCV treatment (negative selection). <br />                                             (PPT) <br />                                             S4 Fig. Persistence CYP51 HKO1 + CYP + PAC2 strain. CYP51 persistence as- <br />                                             sessed qPCR (A) Western blot (B) following seven weeks GCV selection. Sterol <br />  <br />  <br />  <br /> PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003588   March 13, 2015                                                     13 / 17 <br />                                                                                                               Essentiality Leishmania donovani CYP51 <br />  <br />  <br />  <br />                                             profiles ergosterol levels determined GC-MS (C). Chol., cholesterol. <br />                                             Erg, ergosterol. <br />                                             (PPT) <br />                                             S5 Fig. Alignment L. major L. donovani CYP51. A, Clustal Omega alignment. &#206;&#178; 1&#226;&#8364;&#8220;1 <br />                                             1&#226;&#8364;&#8220;2 helices positioned [12]. B, Secondary structure alignment. 3-D models L. <br />                                             major L. donovani CYP51 generated using I-TASSER server. The scoring <br />                                             models overlaid using UCSF Chimera. Red, L. donovani. Blue, L. major. <br />                                             (PPT) <br />                                             S1 Table. Oligonucleotides used study. <br />                                             (XLS) <br />                                             S2 Table. Susceptibility L. major CYP51 inhibitors (EC50, &#206;&#188;M). <br />                                             (DOC) <br />                                             S3 Table. Susceptibility intracellular L. donovani amastigotes select CYP51 inhibitors. <br />                                             (DOC) <br />  <br />  <br />                                             Acknowledgments <br />                                             We wish thank Dr Stephen Beverley, Washington University St. Louis, providing the <br />                                             pXNG4 plasmid, Dr Julio Urbina, Venezuelan Institute Scientific Research (IVIC), fruit- <br />                                             ful discussions suggestions, Dr Claudia Calvet anti-CYP51 antibody, Dr Paul <br />                                             Michels, Universit&#195;&#169; catholique Louvain, Bruxelles anti-GAPDH antibody, Brian <br />                                             Suzuki help intravenous infections. The authors thank Ortiz Montel- <br />                                             lano laboratory UCSF use GC-MS instrument. <br />  <br />                                             Author Contributions <br />                                             Conceived designed experiments: LIM GDM WRR LMP JHM. Performed experi- <br />                                             ments: LIM AEA JYC DFV GDM JBJ DK. Analyzed data: LIM DFV JBJ SC JLSN. Contrib- <br />                                             uted reagents/materials/analysis tools: JYC WRR LMP JHM. Wrote paper: LIM JYC. <br />  <br />                                             References <br />                                              1.   Murray HW, Berman JD, Davies CR, Saravia NG (2005) Advances leishmaniasis. Lancet 366: <br />                                                   1561&#226;&#8364;&#8220;1577. PMID: 16257344 <br />                                              2.   McCall LI, McKerrow JH (2014) Determinants disease phenotype trypanosomatid parasites. <br />                                                   Trends Parasitology 30: 342&#226;&#8364;&#8220;349. doi: 10.1016/j.pt.2014.05.001 PMID: 24946952 <br />                                              3.   McCall LI, Zhang WW, Matlashewski G (2013) Determinants development visceral leishmani- <br />                                                   asis disease. PLoS Pathog 9: e1003053. doi: 10.1371/journal.ppat.1003053 PMID: 23300451 <br />                                              4.   Desjeux P (2004) Leishmaniasis: current situation new perspectives. Comp Immunol Microbiol In- <br />                                                   fect Dis 27: 305&#226;&#8364;&#8220;318. PMID: 15225981 <br />                                              5.   Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, et al. (2012) Leishmaniasis Worldwide Global Es- <br />                                                   timates Its Incidence. Plos One 7: e35671. doi: 10.1371/journal.pone.0035671 PMID: 22693548 <br />                                              6.   Hotez PJ, Alvarado M, Basanez MG, Bolliger I, Bourne R, et al. (2014) The global burden disease <br />                                                   study 2010: interpretation implications neglected tropical diseases. PLoS Negl Trop Dis 8: <br />                                                   e2865. doi: 10.1371/journal.pntd.0002865 PMID: 25058013 <br />                                              7.   Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW (2010) Single-Dose Liposomal Amphotericin B <br />                                                   Visceral Leishmaniasis India. New England Journal Medicine 362: 504&#226;&#8364;&#8220;512. doi: 10.1056/ <br />                                                   NEJMoa0903627 PMID: 20147716 <br />                                              8.   Khalil EA, Weldegebreal T, Younis BM, Omollo R, Musa AM, et al. (2014) Safety Efficacy Single <br />                                                   Dose versus Multiple Doses AmBisome(R) Treatment Visceral Leishmaniasis Eastern Africa: <br />                                                   A Randomised Trial. PLoS Negl Trop Dis 8: e2613. doi: 10.1371/journal.pntd.0002613 PMID: <br />                                                   24454970 <br />  <br />  <br />  <br />  <br /> PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003588    March 13, 2015                                                             14 / 17 <br />                                                                                                                 Essentiality Leishmania donovani CYP51 <br />  <br />  <br />  <br />                                              9.   Monge-Maillo B, Lopez-Velez R (2013) Therapeutic options visceral leishmaniasis. Drugs 73: <br />                                                   1863&#226;&#8364;&#8220;1888. doi: 10.1007/s40265-013-0133-0 PMID: 24170666 <br />                                             10.   Lepesheva GI, Waterman MR (2011) Sterol 14alpha-demethylase (CYP51) therapeutic target for <br />                                                   human trypanosomiasis leishmaniasis. Current topics medicinal chemistry 11: 2060&#226;&#8364;&#8220;2071. <br />                                                   PMID: 21619513 <br />                                             11.   Souza W, Rodrigues JC (2009) Sterol Biosynthesis Pathway Target Anti-trypanosomatid <br />                                                   Drugs. Interdisciplinary perspectives infectious diseases 2009: 642502. doi: 10.1155/2009/642502 <br />                                                   PMID: 19680554 <br />                                             12.   Hargrove TY, Wawrzak Z, Liu J, Nes WD, Waterman MR, et al. (2011) Substrate preferences cata- <br />                                                   lytic parameters determined structural characteristics sterol 14alpha-demethylase (CYP51) from <br />                                                   Leishmania infantum. J Biol Chem 286: 26838&#226;&#8364;&#8220;26848. doi: 10.1074/jbc.M111.237099 PMID: <br />                                                   21632531 <br />                                             13.   Choi JY, Podust LM, Roush WR (2014) Drug Strategies Targeting CYP51 Neglected Tropical Dis- <br />                                                   eases. Chemical Reviews. E-pub ahead print. <br />                                             14.   Xu W, Hsu F-F, Baykal E, Huang J, Zhang K (2014) Sterol Biosynthesis Is Required Heat Resis- <br />                                                   tance Not Extracellular Survival Leishmania. PLoS Pathog 10: e1004427. doi: 10.1371/journal. <br />                                                   ppat.1004427 PMID: 25340392 <br />                                             15.   Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, et al. (2007) Cutaneous leishmaniasis. <br />                                                   The Lancet infectious diseases 7: 581&#226;&#8364;&#8220;596. PMID: 17714672 <br />                                             16.   Berman JD (1982) In vitro susceptibility antimony-resistant Leishmania alternative drugs. The <br />                                                   Journal infectious diseases 145: 279. PMID: 6274970 <br />                                             17.   Gebre-Hiwot A, Frommel D (1993) The in-vitro anti-leishmanial activity inhibitors ergosterol biosyn- <br />                                                   thesis. The Journal antimicrobial chemotherapy 32: 837&#226;&#8364;&#8220;842. PMID: 8144423 <br />                                             18.   Beach DH, Goad LJ, Holz GG Jr. (1988) Effects antimycotic azoles growth sterol biosynthesis <br />                                                   Leishmania promastigotes. Molecular Biochemical Parasitology 31: 149&#226;&#8364;&#8220;162. PMID: 2847043 <br />                                             19.   Al-Abdely HM, Graybill JR, Loebenberg D, Melby PC (1999) Efficacy triazole SCH 56592 against <br />                                                   Leishmania amazonensis Leishmania donovani experimental murine cutaneous visceral <br />                                                   leishmaniases. Antimicrobial Agents Chemotherapy 43: 2910&#226;&#8364;&#8220;2914. PMID: 10582881 <br />                                             20.   Gangneux JP, Dullin M, Sulahian A, Garin YJ, Derouin F (1999) Experimental evaluation second-line <br />                                                   oral treatments visceral leishmaniasis caused Leishmania infantum. Antimicrobial Agents and <br />                                                   Chemotherapy 43: 172&#226;&#8364;&#8220;174. PMID: 9869587 <br />                                             21.   Hart DT, Lauwers WJ, Willemsens G, Vanden Bossche H, Opperdoes FR (1989) Perturbation sterol <br />                                                   biosynthesis itraconazole ketoconazole Leishmania mexicana mexicana infected macro- <br />                                                   phages. Molecular Biochemical Parasitology 33: 123&#226;&#8364;&#8220;134. PMID: 2542790 <br />                                             22.   Berman JD, Goad LJ, Beach DH, Holz GG (1986) Effects Ketoconazole Sterol Biosynthesis by <br />                                                   Leishmania-Mexicana Mexicana Amastigotes Murine Macrophage Tumor-Cells. Molecular Bio- <br />                                                   chemical Parasitology 20: 85&#226;&#8364;&#8220;92. PMID: 3736597 <br />                                             23.   Berman JD, Gallalee JV (1987) In vitro antileishmanial activity inhibitors steroid biosynthesis and <br />                                                   combinations antileishmanial agents. The Journal parasitology 73: 671&#226;&#8364;&#8220;673. PMID: 3037057 <br />                                             24.   Goad LJ, Holz GG Jr., Beach DH (1985) Sterols ketoconazole-inhibited Leishmania mexicana mexi- <br />                                                   cana promastigotes. Molecular Biochemical Parasitology 15: 257&#226;&#8364;&#8220;279. PMID: 4033689 <br />                                             25.   McCall LI, Matlashewski G (2012) Involvement Leishmania donovani virulence factor A2 pro- <br />                                                   tection heat oxidative stress. Exp Parasitol 132: 109&#226;&#8364;&#8220;115. doi: 10.1016/j.exppara.2012.06. <br />                                                   001 PMID: 22691540 <br />                                             26.   Aslett M, Aurrecoechea C, Berriman M, Brestelli J, Brunk BP, et al. (2010) TriTrypDB: functional ge- <br />                                                   nomic resource Trypanosomatidae. Nucleic Acids Research 38: D457&#226;&#8364;&#8220;D462. doi: 10.1093/nar/ <br />                                                   gkp851 PMID: 19843604 <br />                                             27.   Murta SM, Vickers TJ, Scott DA, Beverley SM (2009) Methylene tetrahydrofolate dehydrogenase/cyclo- <br />                                                   hydrolase synthesis 10-CHO-THF essential Leishmania major. Mol Microbiol 71: <br />                                                   1386&#226;&#8364;&#8220;1401. doi: 10.1111/j.1365-2958.2009.06610.x PMID: 19183277 <br />                                             28.   Robinson KA, Beverley SM (2003) Improvements transfection efficiency tests RNA interfer- <br />                                                   ence (RNAi) approaches protozoan parasite Leishmania. Molecular Biochemical Parasitolo- <br />                                                   gy 128: 217&#226;&#8364;&#8220;228. PMID: 12742588 <br />                                             29.   Medinaacosta E, Cross GAM (1993) Rapid Isolation DNA Trypanosomatid Protozoa Using a <br />                                                   Simple Mini-Prep Procedure. Molecular Biochemical Parasitology 59: 327&#226;&#8364;&#8220;329. PMID: 8341329 <br />                                             30.   Livak KJ, Schmittgen TD (2001) Analysis relative gene expression data using real-time quantitative <br />                                                   PCR 2(T)(-Delta Delta C) method. Methods 25: 402&#226;&#8364;&#8220;408. PMID: 11846609 <br />  <br />  <br />  <br />  <br /> PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003588    March 13, 2015                                                                15 / 17 <br />                                                                                                                Essentiality Leishmania donovani CYP51 <br />  <br />  <br />  <br />                                             31.   Downing T, Imamura H, Decuypere S, Clark TG, Coombs GH, et al. (2011) Whole genome sequencing <br />                                                   multiple Leishmania donovani clinical isolates provides insights population structure mecha- <br />                                                   nisms drug resistance. Genome Research 21: 2143&#226;&#8364;&#8220;2156. doi: 10.1101/gr.123430.111 PMID: <br />                                                   22038251 <br />                                             32.   McCall LI, Matlashewski G (2010) Localization induction A2 virulence factor Leishmania: <br />                                                   evidence A2 stress response protein. Mol Microbiol 77: 518&#226;&#8364;&#8220;530. doi: 10.1111/j.1365-2958. <br />                                                   2010.07229.x PMID: 20497497 <br />                                             33.   Gunatilleke SS, Calvet CM, Johnston JB, Chen CK, Erenburg G, et al. (2012) Diverse inhibitor chemo- <br />                                                   types targeting Trypanosoma cruzi CYP51. PLoS Negl Trop Dis 6: e1736. doi: 10.1371/journal.pntd. <br />                                                   0001736 PMID: 22860142 <br />                                             34.   Choi JY, Calvet CM, Vieira DF, Gunatilleke SS, Cameron MD, et al. (2014) R-Configuration 4-Amino- <br />                                                   pyridyl-Based Inhibitors CYP51 Confers Superior Efficacy Against Trypanosoma cruzi. Acs Medici- <br />                                                   nal Chemistry Letters 5: 434&#226;&#8364;&#8220;439. doi: 10.1021/ml500010m PMID: 24900854 <br />                                             35.   Choi JY, Calvet CM, Gunatilleke SS, Ruiz C, Cameron MD, et al. (2013) Rational development 4- <br />                                                   aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 anti-chagas agents. Journal of <br />                                                   Medicinal Chemistry 56: 7651&#226;&#8364;&#8220;7668. doi: 10.1021/jm401067s PMID: 24079662 <br />                                             36.   Calvet CM, Vieira DF, Choi JY, Kellar D, Cameron MD, et al. (2014) 4-Aminopyridyl-based CYP51 in- <br />                                                   hibitors anti-Trypanosoma cruzi drug leads improved pharmacokinetic profile vivo poten- <br />                                                   cy. Journal Medicinal Chemistry 57: 6989&#226;&#8364;&#8220;7005. doi: 10.1021/jm500448u PMID: 25101801 <br />                                             37.   Rogers MB, Hilley JD, Dickens NJ, Wilkes J, Bates PA, et al. (2011) Chromosome gene copy num- <br />                                                   ber variation allow major structural change species strains Leishmania. Genome Re- <br />                                                   search 21: 2129&#226;&#8364;&#8220;2142. doi: 10.1101/gr.122945.111 PMID: 22038252 <br />                                             38.   Ubeda JM, Raymond F, Mukherjee A, Plourde M, Gingras H, et al. (2014) Genome-wide stochastic <br />                                                   adaptive DNA amplification direct inverted DNA repeats parasite leishmania. PLoS biology <br />                                                   12: e1001868. doi: 10.1371/journal.pbio.1001868 PMID: 24844805 <br />                                             39.   Dacher M, Morales MA, Pescher P, Leclercq O, Rachidi N, et al. (2014) Probing druggability biolog- <br />                                                   ical function essential proteins Leishmania combining facilitated null mutant plasmid shuffle <br />                                                   analyses. Mol Microbiol. <br />                                             40.   Norris-Mullins B, VanderKolk K, Vacchina P, Joyce MV, Morales MA (2014) LmaPA2G4, Homolog of <br />                                                   Human Ebp1, Is Essential Gene Inhibits Cell Proliferation L. major. PLoS Negl Trop Dis 8: <br />                                                   e2646. doi: 10.1371/journal.pntd.0002646 PMID: 24421916 <br />                                             41.   Podust LM, von Kries JP, Eddine AN, Kim Y, Yermalitskaya LV, et al. (2007) Small-molecule scaffolds <br />                                                   CYP51 inhibitors identified high-throughput screening defined X-ray crystallography. Anti- <br />                                                   microbial Agents Chemotherapy 51: 3915&#226;&#8364;&#8220;3923. PMID: 17846131 <br />                                             42.   Vieira DF, Choi JY, Roush WR, Podust LM (2014) Expanding binding envelope CYP51 inhibitors <br />                                                   targeting Trypanosoma cruzi 4-Aminopyridyl-based sulfonamide derivatives. Chembiochem: Eu- <br />                                                   ropean journal chemical biology 15: 1111&#226;&#8364;&#8220;1120. doi: 10.1002/cbic.201402027 PMID: 24771705 <br />                                             43.   Chen CK, Doyle PS, Yermalitskaya LV, Mackey ZB, Ang KK, et al. (2009) Trypanosoma cruzi CYP51 <br />                                                   inhibitor derived Mycobacterium tuberculosis screen hit. PLoS Negl Trop Dis 3: e372. doi: 10. <br />                                                   1371/journal.pntd.0000372 PMID: 19190730 <br />                                             44.   Doyle PS, Chen CK, Johnston JB, Hopkins SD, Leung SS, et al. (2010) A nonazole CYP51 inhibitor <br />                                                   cures Chagas0 disease mouse model acute infection. Antimicrobial Agents Chemotherapy <br />                                                   54: 2480&#226;&#8364;&#8220;2488. doi: 10.1128/AAC.00281-10 PMID: 20385875 <br />                                             45.   Lepesheva GI, Waterman MR (2011) Structural basis conservation CYP51 family. Biochimica <br />                                                   Et Biophysica Acta 1814: 88&#226;&#8364;&#8220;93. doi: 10.1016/j.bbapap.2010.06.006 PMID: 20547249 <br />                                             46.   Cherkesova TS, Hargrove TY, Vanrell MC, Ges I, Usanov SA, et al. (2014) Sequence variation in <br />                                                   CYP51A Y strain Trypanosoma cruzi alters sensitivity inhibition. Febs Letters 588: <br />                                                   3878&#226;&#8364;&#8220;3885. doi: 10.1016/j.febslet.2014.08.030 PMID: 25217832 <br />                                             47.   Kulkarni MM, Reddy N, Gude T, McGwire BS (2013) Voriconazole suppresses growth Leishman- <br />                                                   ia species vitro. Parasitology Research 112: 2095&#226;&#8364;&#8220;2099. doi: 10.1007/s00436-013-3274-x PMID: <br />                                                   23392902 <br />                                             48.   Paniz Mondolfi AE, Stavropoulos C, Gelanew T, Loucas E, Perez Alvarez AM, et al. (2011) Successful <br />                                                   treatment Old World cutaneous leishmaniasis caused Leishmania infantum posaconazole. <br />                                                   Antimicrobial Agents Chemotherapy 55: 1774&#226;&#8364;&#8220;1776. doi: 10.1128/AAC.01498-10 PMID: <br />                                                   21282455 <br />                                             49.   Rangel H, Dagger F, Hernandez A, Liendo A, Urbina JA (1996) Naturally azole-resistant Leishmania <br />                                                   braziliensis promastigotes rendered susceptible presence terbinafine: comparative study <br />                                  <br /> </body></html>